Neurology
Found 12 results
Filters: Author is Perumal, Jai S  [Clear All Filters]
2022
Marcille M, Rúa SHurtado, Tyshkov C, Jaywant A, Comunale J, Kaunzner UW, Nealon N, Perumal JS, Zexter L, Zinger N et al..  2022.  Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.. Sci Rep. 12(1):4411.
2018
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. Mult Scler. 24(4):540-542.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.
2017
Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, Gauthier SA.  2017.  Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.. J Neuroimaging. 27(3):333-338.
2016
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.
2015
Babij R, Perumal JS.  2015.  Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.. Neuropsychiatr Dis Treat. 11:1221-9.
Perumal JS, Kister I, Howard J, Herbert J.  2015.  Disease exacerbation after rituximab induction in neuromyelitis optica.. Neurol Neuroimmunol Neuroinflamm. 2(1):e61.
2013
Vargas WS, Perumal JS.  2013.  Fingolimod and cardiac risk: latest findings and clinical implications.. Ther Adv Drug Saf. 4(3):119-24.
Reardon J, Perumal JS.  2013.  Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.. Drug Des Devel Ther. 7:1187-93.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.